- Home
- CMPS vs DRUG Comparison
CMPS vs DRUG Comparison
Compare CMPS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- DRUG
- Stock Information
- Founded
- CMPS 2020
- DRUG 2019
- Country
- CMPS United Kingdom
- DRUG United States
- Employees
- CMPS N/A
- DRUG N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- DRUG Pharmaceuticals and Biotechnology
- Sector
- CMPS Health Care
- DRUG Health Care
- Exchange
- CMPS Nasdaq
- DRUG Nasdaq
- Market Cap
- CMPS 280.2M
- DRUG 260.6M
- IPO Year
- CMPS 2020
- DRUG N/A
- Fundamental
- Price
- CMPS $3.64
- DRUG $35.49
- Analyst Decision
- CMPS Strong Buy
- DRUG Strong Buy
- Analyst Count
- CMPS 6
- DRUG 3
- Target Price
- CMPS $33.60
- DRUG $80.00
- AVG Volume (30 Days)
- CMPS 1.1M
- DRUG 74.4K
- Earning Date
- CMPS 02-27-2025
- DRUG 12-31-2024
- Dividend Yield
- CMPS N/A
- DRUG N/A
- EPS Growth
- CMPS N/A
- DRUG N/A
- EPS
- CMPS N/A
- DRUG N/A
- Revenue
- CMPS N/A
- DRUG N/A
- Revenue This Year
- CMPS N/A
- DRUG N/A
- Revenue Next Year
- CMPS N/A
- DRUG N/A
- P/E Ratio
- CMPS N/A
- DRUG N/A
- Revenue Growth
- CMPS N/A
- DRUG N/A
- 52 Week Low
- CMPS $3.17
- DRUG $0.93
- 52 Week High
- CMPS $12.75
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- CMPS 42.17
- DRUG 43.28
- Support Level
- CMPS $3.29
- DRUG $35.02
- Resistance Level
- CMPS $3.62
- DRUG $38.00
- Average True Range (ATR)
- CMPS 0.41
- DRUG 3.00
- MACD
- CMPS -0.03
- DRUG -0.40
- Stochastic Oscillator
- CMPS 23.11
- DRUG 14.67
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.